Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun;34(6):3795-3812.
doi: 10.1007/s00330-023-10371-2. Epub 2023 Nov 22.

Assessment of arterial-phase hyperenhancement and late-phase washout of hepatocellular carcinoma-a meta-analysis of contrast-enhanced ultrasound (CEUS) with SonoVue® and Sonazoid®

Jie Ren  1 , Qiang Lu  2 , Xiang Fei  3 , Yi Dong  4 , Mirko D Onofrio  5 , Paul S Sidhu  6 , Christoph F Dietrich  7
Affiliations
Review

Assessment of arterial-phase hyperenhancement and late-phase washout of hepatocellular carcinoma-a meta-analysis of contrast-enhanced ultrasound (CEUS) with SonoVue® and Sonazoid®

Jie Ren et al. Eur Radiol. 2024 Jun.

Abstract

Objectives: The recognition of arterial phase hyperenhancement (APHE) and washout during the late phase is key for correct diagnosis of hepatocellular carcinoma (HCC) with contrast-enhanced ultrasound (CEUS). This meta-analysis was conducted to compare SonoVue®-enhanced and Sonazoid®-enhanced ultrasound in the assessment of HCC enhancement and diagnosis.

Methods: Studies were included in the analysis if they reported data for HCC enhancement in the arterial phase and late phase for SonoVue® or in the arterial phase and Kupffer phase (KP) for Sonazoid®. Forty-two studies (7502 patients) with use of SonoVue® and 30 studies (2391 patients) with use of Sonazoid® were identified. In a pooled analysis, the comparison between SonoVue® and Sonazoid® CEUS was performed using chi-square test. An inverse variance weighted random-effect model was used to estimate proportion, sensitivity, and specificity along with 95% confidence interval (CI).

Results: In the meta-analysis, the proportion of HCC showing APHE with SonoVue®, 93% (95% CI 91-95%), was significantly higher than the proportion of HCC showing APHE with Sonazoid®, 77% (71-83%) (p < 0.0001); similarly, the proportion of HCC showing washout at late phase/KP was significantly higher with SonoVue®, 86% (83-89%), than with Sonazoid®, 76% (70-82%) (p < 0.0001). The sensitivity and specificity for the detection of APHE plus late-phase/KP washout detection in HCC were also higher with SonoVue® than with Sonazoid® (sensitivity 80% vs 52%; specificity 80% vs 73% in studies within unselected patient populations).

Conclusion: APHE and late washout in HCC are more frequently observed with SonoVue® than with Sonazoid®. This may affect the diagnostic performance of CEUS in the diagnosis of HCCs.

Clinical relevance statement: Meta-analysis data show the presence of key enhancement features for diagnosis of hepatocellular carcinoma is different between ultrasound contrast agents, and arterial hyperenhancement and late washout are more frequently observed at contrast-enhanced ultrasound with SonoVue® than with Sonazoid®.

Key points: • Dynamic enhancement features are key for imaging-based diagnosis of HCC. • Arterial hyperenhancement and late washout are more often observed in HCCs using SonoVue®-enhanced US than with Sonazoid®. • The existing evidence for contrast-enhanced US may need to be considered being specific to the individual contrast agent.

Keywords: Contrast agents; Hepatocellular carcinoma; Sonazoid; Sonovue; Ultrasound.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Dietrich CF, Nolsøe CP, Barr RG et al (2020) Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liver-Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultrasound Med Biol 46:2579–2604
    1. Dietrich CF, Nolsøe CP, Barr RG et al (2020) Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver - Update 2020 - WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultraschall Med 41:562–585
    1. Dietrich CF, Tannapfel A, Jang HJ, Kim TK, Burns PN, Dong Y (2019) Ultrasound imaging of hepatocellular adenoma using the new histology classification. Ultrasound Med Biol 45:1–10 - DOI - PubMed
    1. Kono Y, Lyshchik A, Cosgrove D et al (2017) Contrast enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System (LI-RADI)): the official version by the American College of Radiology (ACR). Ultraschall Med 38:85–86
    1. Dietrich CF, Mertens JC, Braden B, Schuessler G, Ott M, Ignee A (2007) Contrast-enhanced ultrasound of histologically proven liver hemangiomas. Hepatology 45:1139–1145 - DOI - PubMed

LinkOut - more resources